Cannabis Testing
Since 2018 Brightlabs possesses an opium exemption from the BMC (Bureau for Medicinal Cannabis), for the analysis of cannabis and related products. The combination of this opium exemption, combined with our GMP accreditation, makes Brightlabs an important partner for the analysis of cannabis and related materials for the Pharmaceutical industry, research institutes and supplements sector. Starting in 2023 Brightlabs is analyzing the cannabis and hashish for the Dutch closed coffeeshop chain.
Every year Brightlabs receives thousands of cannabis samples for the analysis of cannabinoids, terpenes or unwanted pollutants like heavy metals or microbiological burden.
By now Brightlabs has ample experience with the analysis of a wide range of products such as CBD-oil and candy, as the analysis of pharmaceutical products, ranging from hand sanitizer to medicinal cannabis in conformity with the current Pharmacopoeia.
Related articles
Spatial distribution of cannabinoid content within a plant
In order to setup a sampling protocol, Brightlabs has investigated together with the CFC consortium the cannabinoide profile over a cannabis plant.
Contact
Questions? Please feel free to contact us.